Manufactuers report positive phase III data for ibrexafungerp for treatment of severe fungal infections in the hospital setting

Analysis of interim data from ongoing CARES and FURI studies notes complete or partial response rate of 80% and 62% respectively, in patients with invasive candidiasis/candidaemia treated with this investigational triterpenoid antifungal.

Source:

Biospace Inc.